Related Experiment Videos
L-carnitine administration in coronary artery disease and cardiomyopathy
Insights
Carnitine supplementation shows benefits for patients with coronary artery disease (CAD), reducing ischemia and improving cardiac performance. Further research is needed to explore its full potential in managing heart conditions.
Area of Science:
- Cardiology
- Biochemistry
Background:
- Myocardial ischemia results from an imbalance between cardiac energy supply and demand, often due to coronary artery disease (CAD).
- In CAD, obstructed arteries limit oxygen supply, hindering energy production to meet the heart's workload.
Purpose of the Study:
- To evaluate the effects of carnitine supplementation in patients with coronary artery disease (CAD).
- To assess carnitine's impact on cardiac performance and ischemia markers.
Main Methods:
- Review of several reports involving approximately 2500 CAD patients.
- Administration of carnitine for up to 1 year.
Main Results:
- Carnitine administration led to reduced ST-segment depression and angina.
- Improved effort tolerance and decreased need for cardiac medications were observed.
- Overall improvement in cardiac performance in CAD and cardiomyopathy patients.
Conclusions:
- Carnitine demonstrates beneficial effects in managing myocardial ischemia and improving cardiac function in CAD patients.
- Further studies are warranted to elucidate carnitine's role in free radical scavenging beyond its established benefits in fatty acid metabolism.
- Oral carnitine up to 2g/day in divided doses appears safe, with mild nausea/vomiting as potential side effects. Intravenous L-carnitine offers rapid action without reported side effects.
Abstract:
Myocardial ischaemia may be defined as a deficiency in cardiac energy supply relative to energy demand. In coronary artery disease (CAD), oxygen supply is limited due to coronary obstruction so energy production is not enough to meet the energy demands for work. Several reports involving about 2500 patients of CAD where carnitine was administered for upto 1 year indicate some beneficial effects. There is reduction in ischaemia showing reduced ST-segment depression and angina, greater effort tolerance and decreased need of cardiac drugs. Carnitine can cause overall improvement in cardiac performance in patients with CAD as well as in cardiomyopathy. More studies are necessary to demonstrate where carnitine can scavenge free radicals apart from its beneficial effect on fatty acid metabolism. Side effects of carnitine are mild nausea and vomiting and dose upto 2 g/day in 3 divided doses may not have any side effects. Intravenous L-carnitine acts rapidly and has no side effects.